Kalvista Pharmaceuticals Inc (KALV) Stock Analysis

Kalvista Pharmaceuticals Inc (KALV) is a publicly traded company in the HEALTHCARE sector. It trades at $26.94, carries a market capitalization of $1.43B. This page summarizes the public market data, fundamentals, and frequently asked questions for KALV, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Kalvista Pharmaceuticals Inc currently has a Neutral sentiment score of 0.10.

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative small-molecule protease inhibitors for unmet medical conditions. The company focuses on therapeutic areas such as hereditary angioedema and diabetic macular edema, utilizing its proprietary drug development platform to create targeted treatments. With a strong pipeline of candidates and strategic partnerships, KalVista is well-positioned to m...

GNG Research Analysis

GNG Research scores Kalvista Pharmaceuticals Inc (KALV) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KALV.

Frequently Asked Questions

Does KALV pay dividends?

Kalvista Pharmaceuticals Inc (KALV) does not currently pay a regular dividend.

What is KALV's market cap?

Kalvista Pharmaceuticals Inc (KALV) has a market capitalization of $1.43B with a current stock price of $26.94.